May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Temporal Variability of OCT in Retinal Vein Occlusion Participants in the SCORE Study
Author Affiliations & Notes
  • N. L. Oden
    The EMMES Corporation, Rockville, Maryland
  • P. C. VanVeldhuisen
    The EMMES Corporation, Rockville, Maryland
  • I. U. Scott
    Depts of Ophthalmology and Health Evaluation Sciences, Penn State College of Medicine, Hershey, Pennsylvania
  • M. S. Ip
    Fundus Photograph Reading Center, University of Wisconsin, Madison, Wisconsin
  • B. A. Blodi
    Fundus Photograph Reading Center, University of Wisconsin, Madison, Wisconsin
  • SCORE Investigator Group
    The EMMES Corporation, Rockville, Maryland
  • Footnotes
    Commercial Relationships N.L. Oden, None; P.C. VanVeldhuisen, None; I.U. Scott, None; M.S. Ip, None; B.A. Blodi, None.
  • Footnotes
    Support National Eye Institute (National Institutes of Health, Department of Health and Human Services) grants 5U10EY014351, 5U10EY014352, and 5U10EY014404. Investigational drug donated by Allergan, Inc.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 107. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      N. L. Oden, P. C. VanVeldhuisen, I. U. Scott, M. S. Ip, B. A. Blodi, SCORE Investigator Group; Temporal Variability of OCT in Retinal Vein Occlusion Participants in the SCORE Study. Invest. Ophthalmol. Vis. Sci. 2007;48(13):107.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To describe test-retest variability of OCT in RVO patients.


Center point and central subfield retinal thickness were measuredby OCT in the first 202 SCORE Study participants twice at screening(V1 and V2: median delay=6 min), and once more 1-3 weeks later(V3: median delay = 11.4d) at randomization. Only patients withall visits were analysed.


Table 1 (changes between timepoints: D12 = V2 - V1; D23 = V3- V2)Means and variancesare fairly constant at each timepoint, but variability of D23significantly exceeds that of D12 (p < 0.001, permutationtest). The disparity remains significant within and constantacross subgroups based on visual acuity, age, disease duration,sex, and diabetes. The absolute value of D23 exceeds that ofD12 in 73%-85% of participants.Table 2 shows that, while V1-V3are highly correlated over time, D12 and D23 tend to be in oppositedirections.Table 2Two clinicalimplications of the data are:1) A 95% confidence interval fortrue retinal thickness of an individual on a particular dayis ±66 µm (center point) and ±28 µm(central subfield).2) Central retinal thickness can change overa few weeks to be outside the 95% range predicted by the same-dayconfidence interval (28% outside for center point, 49% for centralsubfield). 



Our results suggest that observed short-term OCT change is duetomeasurement error plus natural drift over time. Cliniciansand researchers should consider this when using OCT to guidetreatment decisions and when analyzing OCT data.

Clinical Trial: NCT00105027

Keywords: clinical (human) or epidemiologic studies: natural history • imaging/image analysis: clinical 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.